Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while abrdn Physical Palladium Shares ETF trades at $24.81. The key difference: abrdn Physical Palladium Shares ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PALL | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $37.18 |
52-Week Low | $205.48 | $19.96 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $24.87, down 0.96% over 24 hours. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, though oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a buying opportunity. The ETF provides exposure to physical palladium, which has declined 47% from January 2026 highs.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial demand recovery. Investment opportunity exists if palladium prices rebound from current depressed levels, supported by supply risks and potential catch-up trade. Key risks include continued commodity price volatility, Federal Reserve policy uncertainty, and weaker industrial demand affecting palladium's fundamental drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
